Role of perfusion, vascular permeability and anatomic MR imaging in radiation therapy for gliomas;IRM de perfusion, de perméabilité et morphologique: Application en radiothérapie neuro-oncologique

Bulletin du Cancer

Volumn 97, Issue 7, 2010, Pages 753-758

  Dhermain, F ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Anatomic; Glioma; MR; Perfusion MR; Radiotherapy; Vascular permeability

Indexed keywords

BLOOD VESSEL PERMEABILITY; BRAIN MAPPING; BRAIN PERFUSION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CORRELATION ANALYSIS; GLIOMA; HUMAN; IMAGING SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 77955650025     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1146     Document Type: Review

References (39)

1. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997 ; 79 : 1381-93.
2. Kleihues P, Cavenee WK, eds (2000) Pathology and genetics: tumours of the nervous system. In: WHO classification of tumors. Lyon (France): IARC press.
3. Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. Gliomas. WHO and Sainte-Anne hospital classification. Ann Pathol 2000 ; 20 : 413-28.
4. Pallud J, Devaux B, Nataf F, Roux FX, Daumas-Duport C. Spatial delimitation of low grade oligodendrogliomas. Neurochirurgie 2005 ; 51 : 254-9.
5. Ducray F, Dutertre G, Ricard D, Gontier E, Idbaih A, Massard C. Actualités dans la biologie, l'imagerie et le traitement des gliomes de l'adulte. Bull Cancer 2010 ; 97 : 17-36.
6. Martin-Duverneuil N, Guillevin R, Chiras J. Imagerie des gliomes. Cancer Radiother 2008 ; 12 : 669-75.
7. Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck L. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 2006 ; 24 : 1228-35. (Pubitemid 46622025)
8. Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999 ; 211 : 791-8. (Pubitemid 29249482)
9. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003 ; 24 : 1989-98.
10. Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 2007 ; 28 : 455-61.
11. Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiol 2006 ; 48 : 703-13.
12. Law M, Young R, Babb J, Peccerelli N, Chheang S, Gruber ML, et al. Gliomas: predicting time to progression or survival with CBV measurements at dynamic susceptibility-weighted contrast-enhance perfusion MR imaging. Radiology 2008 ; 247 : 490-8.
13. Arvinda HR, Kesavadas C, Sarma PS, Thomas B, Radhakrishnan VV, Gupta AK, et al. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 2009 ; 94 : 87-96.
14. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000 ; 21 : 891-9.
15. Law M, Yang S, Babb J, Knopp EA, Golfinos JG, Zagzag D, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004 ; 25 : 746-55. (Pubitemid 38657655)
16. Quarles CC, Schmainda KM. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magn Reson Med 2007 ; 57 : 680-7.
17. Gambarota G, Leenders W, Maass C, Wesseling P, van der Kogel B, van Tellingen O, et al. Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer 2008 ; 98 : 1784-9. (Pubitemid 351748852)
18. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005 ; 92 : 1599-610.
19. Cao Y, Shen Z, Chenevert TL, Ewing JR. Estimate of vascular permeability and cerebral blood volume using Gd-DPTA Contrast enhancement and dynamic T2*-weighted MRI. J Magn Reson Imaging 2006 ; 24 : 288-96. (Pubitemid 44188553)
20. Dhermain F, Saliou G, Parker F, Page P, Hoang-Xuan K, Lacroix C, et al. Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. J Neurooncol 2010 ; 97 : 81-8.
21. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006 ; 27 : 859-67.
22. Lev MH, Vedolin L. Permeability versus cerebral blood volume measurement in brain tumor evaluation: comparative clinical value and advice to authors. AJNR Am J Neuroradiol 2006 ; 27 : 418-9. (Pubitemid 44897853)
23. Quarles CC, Krouwer HG, Rand SD, Schmainda KM. Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters. Technol Cancer Res Treat 2005 ; 4 : 245-9.
24. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009 ; 29 : 853-60.
25. Cao Y, Tsien CI, Nagesh V, Junck L, Ten Haken R, Ross BD, et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int J Radiat Oncol Biol Phys 2006 ; 64 : 876-85.
26. Galbán CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009 ; 15 : 572-6.
27. Bradley DP, Tessier JJ, Lacey T, Scott M, Jûrgensmeier JM, Odedra R, et al. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 2009 ; 27 : 377-84.
28. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009 ; 69 : 5296-300.
29. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009 ; 30 : 552-8.
30. Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009 ; 253 : 486-96.
31. 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol 2010 ; 37 : 89-97.
32. Meyzer C, Dhermain F, Ducreux D, Habrand JL, Varlet P, Sainte-Rose C, et al. A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI. Radiat Oncol 2010 ; 5 : 9.
33. Giraud P, Kantor G, Loiseau H, Rosenzweig KE. Target definition in the thorax and central nervous system. Semin Radiat Oncol 2005 ; 15 : 146-56. (Pubitemid 40835956)
34. Kantor G, Laprie A, Huchet A, Loiseau H, Dejean C, Mazeron JJ. Radiothérapie des tumeurs gliales : techniques et indications. Cancer Radiother 2008 ; 12 : 687-94.
35. Laprie A. Apport de l'imagerie de spectroscopie de résonance magnétique du proton et des autres imageries métaboliques à la définition des volumes cibles de radiothérapie des tumeurs gliales de l'adulte et de l'enfant. Cancer Radiother 2009 ; 13 : 556-61.
36. 11C-methionine PET: report of three cases. J Neurooncol 2008 ; 87 : 333-9.
37. Dhermain F, Ducreux D, Bidault F, Bruna A, Parker F, Roujeau T, et al. Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma. Bull Cancer 2005 ; 92 : 333-42.
38. Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2008 ; 70 : 773-81.
39. Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J, et al. Association of (11)C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009 ; 73 : 479-85.